Aigen Investment Management LP Buys Shares of 4,485 Blueprint Medicines Co. (NASDAQ:BPMC)

Aigen Investment Management LP purchased a new stake in Blueprint Medicines Co. (NASDAQ:BPMC - Free Report) in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm purchased 4,485 shares of the biotechnology company's stock, valued at approximately $391,000.

A number of other institutional investors have also recently added to or reduced their stakes in the stock. Quarry LP purchased a new stake in Blueprint Medicines in the 3rd quarter valued at $32,000. R Squared Ltd purchased a new stake in shares of Blueprint Medicines in the fourth quarter valued at about $51,000. Covestor Ltd increased its position in Blueprint Medicines by 206.7% during the third quarter. Covestor Ltd now owns 598 shares of the biotechnology company's stock worth $55,000 after purchasing an additional 403 shares during the last quarter. Asset Management One Co. Ltd. purchased a new position in Blueprint Medicines during the fourth quarter worth about $88,000. Finally, Van ECK Associates Corp boosted its holdings in Blueprint Medicines by 48.2% in the 4th quarter. Van ECK Associates Corp now owns 1,116 shares of the biotechnology company's stock valued at $97,000 after purchasing an additional 363 shares during the last quarter.

Wall Street Analysts Forecast Growth

Several research firms have recently commented on BPMC. JMP Securities reaffirmed a "market outperform" rating and set a $125.00 price target on shares of Blueprint Medicines in a research report on Friday, February 14th. Wedbush reaffirmed an "outperform" rating and issued a $128.00 price target on shares of Blueprint Medicines in a research note on Friday, February 28th. Stephens reissued an "overweight" rating and set a $140.00 price objective on shares of Blueprint Medicines in a research report on Thursday, January 2nd. Needham & Company LLC restated a "buy" rating and issued a $133.00 price objective on shares of Blueprint Medicines in a report on Thursday, February 13th. Finally, StockNews.com lowered shares of Blueprint Medicines from a "hold" rating to a "sell" rating in a research note on Monday, March 3rd. Two analysts have rated the stock with a sell rating, six have assigned a hold rating, thirteen have given a buy rating and one has issued a strong buy rating to the company's stock. According to MarketBeat.com, Blueprint Medicines presently has an average rating of "Moderate Buy" and an average price target of $125.21.

Remove Ads

Blueprint Medicines Stock Up 1.2 %

Shares of Blueprint Medicines stock traded up $1.07 during trading on Tuesday, hitting $87.76. 618,419 shares of the stock were exchanged, compared to its average volume of 1,004,362. The stock has a market cap of $5.61 billion, a price-to-earnings ratio of -81.26 and a beta of 0.58. The firm's 50-day moving average price is $99.38 and its 200 day moving average price is $94.16. The company has a debt-to-equity ratio of 1.15, a current ratio of 2.85 and a quick ratio of 2.80. Blueprint Medicines Co. has a 12-month low of $80.68 and a 12-month high of $121.90.

Blueprint Medicines (NASDAQ:BPMC - Get Free Report) last released its quarterly earnings data on Thursday, February 20th. The biotechnology company reported ($0.79) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.68) by ($0.11). Blueprint Medicines had a negative return on equity of 77.49% and a negative net margin of 13.19%. As a group, analysts forecast that Blueprint Medicines Co. will post -1.28 earnings per share for the current fiscal year.

Insider Buying and Selling at Blueprint Medicines

In other Blueprint Medicines news, Director Jeffrey W. Albers sold 15,000 shares of the company's stock in a transaction on Thursday, December 19th. The shares were sold at an average price of $89.77, for a total value of $1,346,550.00. Following the completion of the transaction, the director now owns 157,557 shares in the company, valued at $14,143,891.89. This represents a 8.69 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, insider Ariel Hurley sold 1,819 shares of Blueprint Medicines stock in a transaction dated Thursday, December 12th. The stock was sold at an average price of $93.26, for a total value of $169,639.94. Following the sale, the insider now owns 14,967 shares in the company, valued at $1,395,822.42. This trade represents a 10.84 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 48,427 shares of company stock worth $4,837,801 over the last three months. Insiders own 4.21% of the company's stock.

Blueprint Medicines Profile

Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibitor for the treatment of indolent SM, and other mast cell disorders.